Jul 01, 2024

Guggenheim Biotech

Anyone have a take on this team? Insights on analysts?

410 WSO Academy Equity Research Session Reviews: 4.84/5

Springfield College

Class of '29 Sep 2026 Cohort

5.00/5

Equity Research Mock Coffee Chat

“Michael gave me very practical, specific advice for breaking into equity research as a freshman. I came in with mixed results from past alumni and industry chats, and he showed me how to make them more useful. He advised tailoring the length and questions of each chat to the contact: start with a brief intro, then pivot to targeted questions tied to their role. For shorter calls, he suggested pinpoint questions that draw out actionable advice. When a contact works in a different area, he told me to phrase my interest broadly and then ask for insight into their team or function, so my goals line up with their work. He also changed how I prepare. He told me to read the analyst’s published reports or their firm’s research before the call and to bring one or two stock or sector ideas and ask for their take, which shows I’ve done my homework. He suggested using school resources like terminals and the finance club to gather sources and data. On building my resume, he recommended continuing to publish on a Substack or website, pursuing WSO or part-time research projects, and applying to the WSO equity research internship or similar programs, then adding the published pieces to my resume and portfolio. He also told me to join my school finance club and get Bloomberg access. Finally, he coached me to ask for introductions during the call when it comes up, to repeat the request in the thank-you email, and to explicitly ask who they’d recommend and offer to follow up. I left with clear action items I can start on right away.”

Class of '25 Nov 2026 Cohort

5.00/5

Equity Research Career Roadmap (optional)

“Chris was very easy to talk to and made the session feel relaxed and genuinely useful. He gave me clear, actionable tasks that I can go away and work on straight away to expand my network. I hope to reconvene with him at a later date to discuss the progress I have made and get his feedback on the work I have been doing.”

See All 11,626 WSO Academy Reviews

16 Comments

WSO Monkey Bot

Based on the most helpful WSO content, here are some insights on Guggenheim's Biotech team and analysts:

Healthcare Group Strength:
- Guggenheim's Healthcare (HC) group, which includes Biotech, is one of their strongest teams. This group has been involved in significant deals, such as the Pfizer-Array deal, indicating a solid presence in the industry.
Deal Flow and Placement:
- The Healthcare group, including Biotech, has a strong deal flow compared to other groups within Guggenheim. Analysts from this group tend to have better placement opportunities, especially in buy-side roles. While moving to Mega Funds (MF) is challenging, analysts from the HC group have a higher success rate in securing such positions.
Reputation and Growth:
- Guggenheim has been growing its practice significantly, bringing in senior MDs from other banks. This growth is reflected in their involvement in large deals, although their deal flow is not yet on par with more established elite boutiques or bulge bracket banks.
Exit Opportunities:
- Historically, Guggenheim has had weaker exits to Mega Funds, but this is improving, particularly for analysts in the Healthcare group. Analysts from this group have managed to lateral to top banks like Lazard, Evercore, Moelis, and Centerview, which are known for better exit opportunities.
Technical Experience:
- Analysts in the Healthcare group, including Biotech, gain strong technical experience. This is a key factor that contributes to their better placement and exit opportunities.

In summary, Guggenheim's Biotech team, as part of the broader Healthcare group, is well-regarded for its strong deal flow, technical experience, and improving exit opportunities. The group's growth and involvement in significant deals further enhance its reputation within the industry.

Sources: Honest thoughts on Guggenheim, Guggenheim Partners Investment Banking, Guggenheim top groups and exits (SA2020), Guggenheim Ascending?, https://www.wallstreetoasis.com/forum/investment-banking/thoughts-on-guggenheim-sfguggenheim-in-general?customgpt=1

Quote

Report

Other

I'm an AI bot trained on the most helpful WSO content across 17+ years.

Associate 2 in Research - Other

I know one of their pretty good bio analysts just went to a smaller shop called LifeSci. Was oncology guy

Quote

Report

Other

Analyst 1 in ER

Solid team and I think above market pay. Could be wrong though.

Nothing crazy. Don’t think they have anyone ranked.

Quote

Report

Other

Authored by: Certified Equity Research Professional - 1st Year AnalystCertified Equity Research Pro

Benson Says

Most Helpful

From a research perspective it’s a top MM shop imo, alongside Leerink and Jefferies. One of my first calls on any smid cap names we work on. They’re not as shamelessly promotional as some others (specifically a place whose name rhymes with fairies…). Handful of really strong analysts there - Debjit, Schmidt, Fernandez. One of my analysts religiously follows their “Best Ideas” series and it’s definitely been a +EV tool to have in the arsenal. Can I say the same for Piper or Cantor? Nope lol As for II rankings, not something I really follow, but HC buysiders will look at any Gugg ER resume after a few years. Take my 2c fwiw

Quote

Report

Other

Authored by: Certified Hedge Fund Professional - Investment AnalystCertified Hedge Fund Pro

Analyst 1 in ER

wtf rhymes with fairies bro?

Quote

Report

Other

Authored by: Certified Equity Research Professional - 1st Year AnalystCertified Equity Research Pro

Assistant PM in HF - EquityHedge

Harum eum quam deleniti quo nisi consequuntur fuga sint. In in culpa iusto architecto. Tenetur magnam dolorem quia ut voluptatum expedita et beatae. Unde architecto dignissimos est ducimus a facere.

Facilis tenetur fuga sit earum eos expedita ea. Rem mollitia tenetur aliquid nisi velit. Cum tempore excepturi fugiat cupiditate quo aliquid qui.

Quote

Report

Other

Authored by: Certified Hedge Fund Professional - Investment AnalystCertified Hedge Fund Pro

+13	Is Equity Research Dying - Where Are the Future Opportunites?	4	4d
+10	Associates who stuck around for > 5 years working for the same analyst. Why?	4	1w
+9	Detailed Revenue and Cost Builds	3	1w
+7	Analyst with no coverage or ranking	5	1w
+6	Preparation for grad scheme - buyside ER	1	1d
+1	IB SA -> ER FT	4	2w
0	Equity Research Rankings	1	1w

1	redever	99.2
2	BankonBanking	99.0
3	Secyh62	99.0
4	kanon	99.0
5	Betsy Massar	98.9
6	DrApeman	98.9
7	GameTheory	98.9
8	CompBanker	98.9
9	dosk17	98.9
10	Mimbs	98.8

Elite Career Bootcamp. Top Job Offer Guaranteed.

Elite Career Bootcamp. Top Job Offer Guaranteed.

Guggenheim Biotech

Score Breakdown

Feedback

Score Breakdown

Feedback

Elite Career Bootcamp. Top Job Offer Guaranteed.

Elite Career Bootcamp. Top Job Offer Guaranteed.

Guggenheim Biotech

See All Comments - 100% Free

Trending Content - Equity Research Forum